ARRIVAL: a phase 3b study to assess potential for tezepelumab to reduce maintenance inhaled therapy and induce remission in patients with severe asthma
Year: 2024
Type: conference-paper
Institutions: Brigham and Women's Hospital, Harvard University, Ghent University Hospital, Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Universitätsmedizin Rostock, University of Rostock, National Institute for Health and Care Research, University of Oxford, King's College London, Guy's and St Thomas' NHS Foundation Trust, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Amgen (United States), AstraZeneca (Poland), AstraZeneca (Sweden), AstraZeneca (United States), AstraZeneca (United Kingdom), University of Leicester, NIHR Leicester Biomedical Research Centre
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4404098294